Stryker’s Q2 execution, Mako robotics momentum, and raised full-year outlook support a Buy, though valuation leaves limited room for error. Cybersecurity, supply disruption, and tariff pressure keep the risk profile disciplined.
Stryker Corporation (SYK) merits a Buy rating for moderate-risk investors with a medium-term horizon. The investment case rests on a diversified medical technology platform, strong Q2 2026 execution, the Mako robotics franchise, and a full-year outlook calling for 8.3% to 9.3% organic sales growth and adjusted EPS of $14.95 to $15.10. At the quoted reference price of $330.69, the stock is not a bargain, but the operating recovery and product pipeline provide a credible path toward the report's fair value estimate of $365.00.
The central tension is valuation. SYK trades at 40.2x trailing earnings and 23.1x forward earnings, with a PEG ratio of 1.7 and an enterprise-value-to-revenue ratio of 5.7x. Those figures demand continued execution. Stryker delivered that execution in Q2, posting $6.59 billion of sales, 9.0% organic growth, adjusted EPS of $3.69, and adjusted operating margin of 27.4%. The stock therefore offers quality and growth, but not much room for operational missteps.
The main risks are visible rather than theoretical. A March 11, 2026 cybersecurity incident disrupted production, a peripheral vascular supply issue caused lost sales in Q2, and year-end debt reached $16.0 billion against $4.0 billion of cash. Management also cited remediation costs, raw-material pressure, tariffs, reimbursement pressure, and foreign-exchange exposure. These risks support a disciplined Buy rather than a Strong Buy.
Stryker Corporation (SYK) is a global medical technology company founded in 1941 and headquartered in Portage, Michigan. It employs approximately 56,000 people and sells through company-owned operations, distributors, and dealers in about 61 countries. Its portfolio serves doctors, hospitals, ambulatory settings, and other healthcare facilities across surgical equipment, implants, patient handling, emergency care, neurotechnology, vascular intervention, and connected-care solutions.
Stryker generated $25.1 billion of 2025 revenue and invested $1.6 billion in research and development. The company reported 14,600 owned patents, a scale that supports a steady cadence of product launches. Its operating model combines a large commercial footprint with products embedded in operating rooms, hospital workflows, and orthopedic procedure protocols.
MedSurg and Neurotechnology is the larger segment and delivered Q2 2026 revenue growth of 9.7% to approximately $3.6 billion. Organic growth reached 9.2%, including 8.9% in the United States and 10.5% internationally. Q1 results showed a mixed starting point after the cyber incident, with instruments revenue at $920 million, endoscopy at $868 million, medical at $902 million, and vascular at $517 million.
The segment's Q2 growth was broad. U.S. endoscopy organic sales increased 10.2%, supported by operating-room infrastructure, the Oculon Light, urology, connected operating-room products, and sports medicine. U.S. medical organic sales increased 13.1%, led by Sage, Emergency Care, preoperative skin preparation products, Howard Cots, and LifeVac 35. Instruments posted 8.4% U.S. organic growth, while international MedSurg and Neurotechnology growth reached 10.5%.
Vascular was the weak point. U.S. vascular organic sales declined 6.7% in Q2 because of a supply disruption at a peripheral vascular plant. The hemorrhagic portfolio partly offset the decline through the SURPASS Elite flow diverter. Stryker completed its acquisition of Amplitude Vascular Systems on May 7, 2026, adding intravascular lithotripsy technology to the vascular portfolio.
Orthopaedics generated approximately $3.0 billion of Q2 revenue, up 9.1%, with organic growth of 8.6%. U.S. organic growth reached 9.1% and international growth reached 7.5%. U.S. knees grew 6.2%, hips grew 4.9%, trauma and extremities grew 12.5%, and Orthotech grew 9.2%. The mix shows stronger momentum in trauma, extremities, shoulders, and enabling technologies than in mature large-joint categories.
The Q1 2026 recast reporting structure places Mako and other enabling technologies within Orthotech. That change aligns the reporting structure more closely with the company's internal operations and brings the robotics platform into clearer view. In 2025, the recast Orthopaedics segment generated $11.42 billion, compared with $13.69 billion for MedSurg and Neurotechnology.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Mako is Stryker's most important flagship platform. Management reported the best-ever second quarter for Mako installations in the United States and internationally, along with rising utilization across the installed base. Mako has supported more than 2.5 million procedures globally and systems are installed across 47 countries. The platform now covers hip, knee, spine, and shoulder procedures.
Mako's economics extend beyond the initial capital sale. Each installed system supports surgeon training, procedure utilization, implants, instruments, and future software or hardware upgrades. U.S. knee growth of 6.2% reflected continued Mako adoption, while U.S. Orthotech growth of 9.2% was driven by robust Mako installations. That combination creates a reinforcing loop between capital equipment and consumable procedure revenue.
The full commercial launch of Mako RPS in the United States expands the portfolio with a handheld robotic option for total knee replacement. Mako 4.0 also supports the shoulder application, while the Mako Revive hip platform addresses more difficult primary hip cases and hip revisions. The breadth of applications gives Stryker more opportunities to place systems and increase utilization over time.
Mako is not risk-free. Hospital capital budgets can move unevenly, and the Q2 call described elevated backlog caused partly by production constraints after the cyber incident. The platform also faces competition from robotic and enabling technologies offered by other large medtech companies. Still, the combination of 20 years of Mako development, clinical evidence, a large installed base, and expanding applications gives the product a strong strategic position.
Stryker's competitive advantage comes from scale, breadth, product integration, and a large commercial organization. The company sells across hospital capital equipment, implants, emergency care, endoscopy, instruments, neurotechnology, vascular intervention, and connected-care platforms. That breadth lets a sales force enter through one product category and expand across a hospital's surgical and clinical workflows.
The innovation engine is substantial. Stryker invested $1.6 billion in R&D in 2025 and reported 14,600 owned patents. Q2 launches and approvals included Mako RPS, Triathlon Gold, the Triathlon Medial Stabilized Insert, the Encompass total ankle replacement system, and the Pangaea Trauma Plating System in Europe. Sonopet 3 adds another product refresh in instruments.
The company also benefits from workflow integration. Products such as ProCuity beds, Vocera, care.ai, connected operating-room systems, Mako, and surgical instruments are tied to hospital processes rather than isolated purchases. Replacing an integrated workflow can require training, capital planning, clinical adoption, and operational changes. That creates customer friction that supports retention when product performance remains strong.
Management's stated demand drivers are concrete: an aging population, hospital workforce productivity needs, chronic disease, and continued demand for high-acuity, medically necessary, and emergent procedures. These factors support a durable revenue base. The moat is therefore practical rather than theatrical: scale helps fund innovation, innovation supports adoption, and adoption expands the installed base.
Operations were tested by the March 11, 2026 cybersecurity incident. Stryker reported that production was ramping back up during Q2, with manufacturing, IT, and remediation costs still affecting the 2026 earnings profile. The company also cited loss absorption from factory downtime. Q2 results therefore reflect both a recovery in demand fulfillment and unusual operating costs.
A separate peripheral vascular supply disruption caused a meaningful backorder situation and lost Q2 sales. Management attributed the issue to one plant supporting most of the Inari business's products. The company stated that backorders were expected to reach a manageable level by the end of Q3 and that the vascular business was still expected to grow in Q3 and Q4.
The operational recovery has a visible demand cushion. Stryker exited Q2 with elevated capital-equipment backlog and strong orders, particularly for ProCuity beds and SmartCare products. Management said the constraint was production capacity rather than a lack of customer demand. That distinction supports second-half sales, although it also places execution pressure on manufacturing, logistics, and quality systems.
Q2 adjusted gross margin reached 66.0%, up 60 basis points year over year, while adjusted operating margin reached 27.4%, up 170 basis points. Business mix, cost discipline, and a net tariff benefit helped the quarter. Raw-material pressure, oil costs, tariffs, cybersecurity remediation, and factory absorption costs remain the main operating offsets.
Stryker's 2025 Investor Day identified an $81 billion total addressable market across its major divisions. Orthopaedics represented $30 billion, including a $17 billion joint-replacement market and a $13 billion trauma and extremities market. MedSurg and Neurotechnology represented $51 billion, including endoscopy at $19 billion, medical at $14 billion, neuro cranial at $7 billion, vascular at $6 billion, and instruments at $5 billion.
The strongest market growth categories align with Stryker's product priorities. The Investor Day framework cited mid-single-digit growth through 2028 for joint replacement, trauma and extremities, and endoscopy. Medical, vascular, and instruments were assigned high-single-digit growth outlooks. Mako and enabling technologies add an expansion layer across hip, knee, partial knee, spine, and shoulder procedures.
Care delivery is moving toward outpatient and ambulatory settings. Management specifically described site-of-care shifts toward ambulatory surgery centers and said Stryker's portfolio is positioned to benefit across hips, knees, and other categories. The company's Mako RPS launch also addresses a broader range of care settings, extending the robotics opportunity beyond large hospital installations.
The market remains sensitive to hospital budgets and reimbursement. CMS finalized a 2.6% CY 2026 update for hospital outpatient and ambulatory surgery center payments. That supports provider revenue, but hospital purchasing departments continue to focus on labor savings, throughput, clinical outcomes, and total cost of ownership. Stryker's capital products and connected-care systems are designed around several of those budget priorities.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Stryker's customers include hospitals, ambulatory surgery centers, physicians, surgeons, emergency-care providers, and other healthcare facilities. The customer base is concentrated in professional and institutional buyers rather than direct consumers. Purchasing decisions often involve surgeons, operating-room leaders, supply-chain teams, finance departments, and hospital executives.
The product portfolio serves both planned and urgent care. Joint replacement, spine, and some capital equipment purchases are more discretionary and budget-sensitive. Emergency care, trauma, neurotechnology, patient handling, vascular intervention, and acute-care products support higher-acuity demand. Management said the vast majority of the portfolio supports medically necessary, emergent, or high-acuity procedures.
Customer value increasingly depends on workflow outcomes. ProCuity beds, SmartCare, Vocera, care.ai, connected operating-room products, and Mako all address productivity, coordination, utilization, or clinical precision. That gives Stryker a way to sell beyond the product's purchase price, although the value proposition must withstand hospital budget reviews and reimbursement scrutiny.
Stryker competes with Zimmer Biomet, Johnson & Johnson MedTech's DePuy Synthes, and Smith+Nephew in orthopaedics. Medtronic, Globus Medical, and other specialized companies compete in spine and neurotechnology. Johnson & Johnson MedTech, Medtronic, Boston Scientific, Intuitive Surgical, Getinge, and other equipment providers overlap with Stryker across surgical, procedural, hospital, and robotic categories.
Stryker's main advantage versus narrower orthopedic rivals is breadth across MedSurg, Neurotechnology, and Orthopaedics. Its main advantage versus larger diversified medtech companies is the depth of its orthopaedics and hospital-workflow franchises. The company has enough scale to fund R&D and commercial coverage while maintaining exposure to several separate procedure categories.
Competition remains intense. Stryker's 2025 Form 10-K identifies pricing pressure, product development requirements, regulatory demands, technological obsolescence, and industry consolidation as competitive risks. Larger hospital systems have bargaining power, while surgeons and healthcare facilities can influence product adoption. Mako's installed base and clinical workflow integration help defend the franchise, but they do not eliminate competitive pressure.
Johnson & Johnson's October 2025 intent to separate its orthopaedics business adds another strategic variable. A more focused DePuy Synthes could sharpen competition, or a separation could create transition opportunities for Stryker. The effect depends on execution by both companies, so the relevant fact today is the potential reshaping of a major competitive relationship.
Stryker's Q2 call described U.S. procedure demand as healthy and stable, with capital demand strong and backlog elevated. International organic growth reached 8.9%, led by markets including Australia and New Zealand, Germany, Canada, South Korea, Japan, India, and Brazil. Europe showed some procedure softness, but the company reported broad international growth.
The conflict in Iran had a modest impact on overall company growth during Q2. Management also cited tariffs, oil, raw materials, and foreign currency as operating variables. The 2026 outlook includes a modestly positive pricing impact and a slightly favorable foreign-exchange effect if rates remain near current levels.
Reimbursement policy remains a sector-level pressure point. Management discussed proposed reductions affecting physician reimbursement for large-joint procedures and described a history of proposed rules generating noise before reaching a more reasonable outcome. The company also views ambulatory surgery centers as an opportunity because Stryker sells products across multiple procedure categories in that setting.
Stryker's Form 10-K filed on February 11, 2026 identifies cybersecurity, supply-chain availability, third-party suppliers, regulatory compliance, reimbursement, foreign exchange, tariffs, and acquisition integration as material risk areas. The Q2 cybersecurity recovery and peripheral vascular supply disruption demonstrate that these risks can affect reported results rather than remain footnotes in a filing.
Year-end debt reached $16.0 billion against $4.0 billion of cash, leaving Stryker with leverage that is manageable but worth watching after the cyber incident and remediation costs.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q2 revenue rose to $6.59 billion with 9.0% organic growth, while adjusted operating margin reached 27.4% and adjusted EPS came in at $3.69.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management guided to 8.3% to 9.3% organic sales growth and adjusted EPS of $14.95 to $15.10 for 2026, signaling continued momentum after a strong quarter.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Stryker trades at 40.2x trailing earnings and 23.1x forward earnings, so the stock still depends on flawless execution to justify its premium multiple.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At a quoted reference price of $330.69, the report’s fair value estimate of $365.00 implies upside, but not enough to warrant a Strong Buy.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Stryker Corporation (SYK) is a high-quality medical technology compounder navigating a temporary operational storm. Q2 2026 showed 9.0% organic sales growth, adjusted EPS growth of 17.9%, a 27.4% adjusted operating margin, and stronger demand for capital products. Management's narrowed full-year guidance adds credibility to the recovery case.
The long-term case remains anchored by a broad $81 billion addressable market, 14,600 patents, $1.6 billion of annual R&D investment, and Mako's expanding installed base. The balance sheet and valuation keep the stock from being a screaming deal, while the cyber incident, vascular supply issue, and insider net selling of 972,618 shares add caution.
The resulting stance is Buy, not Strong Buy. Stryker offers a credible path to durable earnings growth and market leadership in surgical technology, but the current multiple requires continued execution. Investors who value business quality, recurring procedure exposure, and medium-term growth can justify ownership near the current reference price, with $365.00 as the report's central valuation anchor.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Stryker is executing well with double-digit revenue growth, strong segment momentum, and raised 2026 EPS guidance. The stock remains a Buy, but the premium valuation argues for patience on pullbacks.
Stryker Corporation (SYK) drops after a disappointing Q1 2026 report, with earnings and revenue both missing estimates. A March cyber incident disrupted operations, slowed sales growth, and pressured margins, even as the company kept full-year guidance unchanged.
Alibaba Group Holding Limited (BABA) gains despite a sharp EPS miss, as the deeper earnings picture shows resilient revenue, fast cloud and AI growth, and aggressive reinvestment. This analysis goes beyond the headline to unpack margin pressure, quick commerce momentum, and what the market may be pricing in.